Takahashi, Nobunori http://orcid.org/0000-0001-6937-3567
Kojima, Toshihisa
Kida, Daihei
Kaneko, Atsushi
Hirano, Yuji
Fujibayashi, Takayoshi
Yabe, Yuichiro
Takagi, Hideki
Oguchi, Takeshi
Hanabayashi, Masahiro
Kato, Takefumi
Funahashi, Koji
Hayashi, Masatoshi
Tsuboi, Seiji
Kanayama, Yasuhide
Sobue, Yasumori
Asai, Nobuyuki
Matsumoto, Takuya
Watanabe, Tatsuo
Asai, Shuji
Ishiguro, Naoki
Article History
Received: 13 February 2019
Revised: 22 April 2019
Accepted: 25 April 2019
First Online: 17 May 2019
Compliance with ethical standards
: This study was approved by the Ethics Committee of Nagoya University Graduate School of Medicine. Written informed consent was obtained from all participants.
: N.I. received grants, lecture fees, and fees for serving on speakers’ bureaus from Daiichi Sankyo, Takeda Pharmaceutical, Hisamitsu Pharmaceutical, Otsuka Pharmaceutical, Taisho Toyama Pharmaceutical, Kaken Pharmaceutical, Eisai, Janssen Pharmaceutical, Bristol-Myers Squibb, Abbott Japan, Chugai Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Astellas Pharma, and Pfizer Japan. T.K. received lecture fees (< US$5000) from Mitsubishi Tanabe Pharma, Takeda Pharma, Eisai Pharma, AbbVie, Bristol-Myers Squibb, and Pfizer and $10,000 from Chugai Pharma. N.T. received speaker’s fees from Abbott Japan, Eisai, Mitsubishi Tanabe Pharma, Pfizer, Chugai Pharmaceutical, and Bristol-Myers Squibb (< $5000). Y.H. received speaker’s fees from Abbott Japan, Eisai, Mitsubishi Tanabe Pharma, Pfizer, Chugai Pharmaceutical, and Bristol-Myers Squibb (< $5000). A.K. received lecture fees (< $5000) from Mitsubishi Tanabe Pharma, Takeda Pharma, Eisai Pharma, Chugai Pharma, Abbott, Bristol-Myers Squibb, UCB, Janssen, and Pfizer. All other authors have no conflict of interest to report.